Multi-center Study to Assess Safety, Tolerability and Efficacy of Topical Pravibismane in Moderate DFI Patients

NCT05174806 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

47

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetic Foot Infection
Diabetic Foot

Interventions

DRUG: Topical Pravibismane
OTHER: Standard of Care

Sponsor

Microbion Corporation

Collaborators

[object Object]
[object Object]
[object Object]